DFTX ▲ +6.6% - Definium Therapeutics, Inc. $DFTX Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder Definium Therapeutics shares rose 6.6% after the company announced positive topline results from its Phase 3 Panorama study of DT120 ODT in generalized anxiety disorder. The successful trial outcome supports the clinical profile of the company's lead candidate and moves the program closer to potential regulatory submission. 14-SEP-2026 07:00 AM ET